Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2021

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Hormone Receptor Positive Breast CarcinomaLocally Advanced Breast CarcinomaMetastatic Breast CarcinomaMetastatic Endometrioid AdenocarcinomaMetastatic Fallopian Tube CarcinomaMetastatic HER2 Negative Breast CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Ovarian CarcinomaMetastatic Primary Peritoneal CarcinomaPrognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRefractory Breast CarcinomaStage IV Fallopian Tube Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Primary Peritoneal Cancer AJCC v8Stage IV Uterine Corpus Cancer AJCC v8Stage IVA Fallopian Tube Cancer AJCC v8Stage IVA Ovarian Cancer AJCC v8Stage IVA Primary Peritoneal Cancer AJCC v8Stage IVA Uterine Corpus Cancer AJCC v8Stage IVB Fallopian Tube Cancer AJCC v8Stage IVB Ovarian Cancer AJCC v8Stage IVB Primary Peritoneal Cancer AJCC v8Stage IVB Uterine Corpus Cancer AJCC v8
Interventions
DRUG

Abexinostat Tosylate

Given PO

DRUG

Fulvestrant

Given IM

DRUG

Palbociclib

Given PO

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Xynomic Pharmaceuticals, Inc.

INDUSTRY

lead

Pamela Munster

OTHER

NCT04498520 - Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | Biotech Hunter | Biotech Hunter